Market intelligence, trend analysis and forecasts for the Pharma and Healthcare industries across the regions

Industry / Czech Republic

7% P&R Reductions Scheduled For January 2010

December 2009 | Industry Trend Analysis

Prospects for growth in the Czech Republic's US$4.2bn pharmaceutical market appear ominous for 2010, pending the resolution of challenges to pricing legislation proposed in late 2009. In an effort to shave CZK2.7bn (US$150mn) off the state health insurance drug budget, a new decree - due to be implemented from January 1 2010 - would see a 7% reduction in both maximum pharmaceutical prices and reimbursement rates. This will cover products that have not undergone annual review from the State Institute for Drug Control (SUKL). BMI is poised to downgrade its forecast for 6.1% local currency growth (16.2% in US dollars)

To read the full article, please choose one of the following options:

Subcribers please log in

Emerging Europe InsightEmerging Europe Channels Emerging Europe Countries